It may also help obese and overweight individuals lose weight, according to a study published in the New England Journal of Medicine. Researchers think this might be “game-changing.”
Tirzepatide, which is also marketed under the name Mounjaro, slows down the rate at which food passes through the digestive tract while imitating hormones that provide feelings of fullness after meals.
This then motivates individuals to eat less, which leads to weight loss. A four-week supply usually costs between £150 and £200.
A Medicines and Healthcare Products Regulatory Agency (MHRA) spokeswoman said after the approval:
“We are happy to report that we have licensed Mounjaro (tirzepatide), a novel class of medication for individuals with type 2 diabetes that is not well managed.
“No medicine would be approved unless it meets our expected standards of safety, quality and effectiveness.”
